| Gene symbol | L1CAM | Synonyms | CAML1, CD171, HSAS, HSAS1, HYCX, MASA, MIC5, N-CAM-L1, N-CAML1, NCAM-L1, S10, SPG1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | L1 cell adhesion molecule | ||||
| GTO ID | GTC3631 |
| Trial ID | NCT06094842 |
| Disease | Prostate Carcinoma | Prostate Small Cell Neuroendocrine Carcinoma |
| Altered gene | L1CAM |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | L1CAM CAR-T cells |
| Co-treatment | Bendamustine|Bridge Therapy |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | A Phase I Safety and Feasibility Study of Cellular Immunotherapy for Extensive Stage Small Cell Neuroendocrine Prostate Cancer Using Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptor |
| Year | 2024 |
| Country | United States |
| Company sponsor | Fred Hutchinson Cancer Center |
| Other ID(s) | RG1123589|NCI-2023-07464|FH20229 |
| Cohort 1 | |||||||||||
|
|||||||||||